• 1
    Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011; 17: 107115.
  • 2
    Ciesek S, Wedemeyer H. Immunosuppression, liver injury and post-transplant HCV recurrence. J Viral Hepat 2012; 19: 18.
  • 3
    Alvisi G, Madan V, Bartenschlager R. Hepatitis C virus and host cell lipids: an intimate connection. RNA Biol 2011; 8: 258269.
  • 4
    Albecka A, Belouzard S, Op de Beeck A, Descamps V, Goueslain L, Bertrand-Michel J, et al. Role of low-density lipoprotein receptor in the hepatitis C virus life cycle. HEPATOLOGY 2012; 55: 9981007.
  • 5
    Zeisel MB, Koutsoudakis G, Schnober EK, Haberstroh A, Blum HE, Cosset FL, et al. Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81. HEPATOLOGY 2007; 46: 17221731.
  • 6
    Sainz B, Jr., Barretto N, Martin DN, Hiraga N, Imamura M, Hussain S, et al. Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. Nat Med 2012; 18: 281285.
  • 7
    Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, et al. Binding of hepatitis C virus to CD81. Science 1998; 282: 938941.
  • 8
    Evans MJ, von Hahn T, Tscherne DM, Syder AJ, Panis M, Wolk B, et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 2007; 446: 801805.
  • 9
    Ploss A, Evans MJ, Gaysinskaya VA, Panis M, You H, de Jong YP, Rice CM. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 2009; 457: 882886.
  • 10
    Rigotti A, Miettinen HE, Krieger M. The role of the high-density lipoprotein receptor SR-BI in the lipid metabolism of endocrine and other tissues. Endocr Rev 2003; 24: 357387.
  • 11
    Acton S, Rigotti A, Landschulz KT, Xu S, Hobbs HH, Krieger M. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science 1996; 271: 518520.
  • 12
    Acton SL, Scherer PE, Lodish HF, Krieger M. Expression cloning of SR-BI, a CD36-related class B scavenger receptor. J Biol Chem 1994; 269: 2100321009.
  • 13
    Rohrl C, Fruhwurth S, Schreier SM, Lohninger A, Dolischka A, Huttinger M, et al. Scavenger receptor, Class B, Type I provides an alternative means for beta-VLDL uptake independent of the LDL receptor in tissue culture. Biochim Biophys Acta 2010; 1801: 198204.
  • 14
    Van Eck M, Hoekstra M, Out R, Bos IS, Kruijt JK, Hildebrand RB, Van Berkel TJ. Scavenger receptor BI facilitates the metabolism of VLDL lipoproteins in vivo. J Lipid Res 2008; 49: 136146.
  • 15
    Gu X, Lawrence R, Krieger M. Dissociation of the high density lipoprotein and low density lipoprotein binding activities of murine scavenger receptor class B type I (mSR-BI) using retrovirus library-based activity dissection. J Biol Chem 2000; 275: 91209130.
  • 16
    Scarselli E, Ansuini H, Cerino R, Roccasecca RM, Acali S, Filocamo G, et al. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J 2002; 21: 50175025.
  • 17
    Catanese MT, Graziani R, von Hahn T, Moreau M, Huby T, Paonessa G, et al. High-avidity monoclonal antibodies against the human scavenger class B type I receptor efficiently block hepatitis C virus infection in the presence of high-density lipoprotein. J Virol 2007; 81: 80638071.
  • 18
    Grove J, Huby T, Stamataki Z, Vanwolleghem T, Meuleman P, Farquhar M, et al. Scavenger receptor BI and BII expression levels modulate hepatitis C virus infectivity. J Virol 2007; 81: 31623169.
  • 19
    Lacek K, Vercauteren K, Grzyb K, Naddeo M, Verhoye L, Slowikowski MP, et al. Novel human SR-BI antibodies prevent infection and dissemination of HCV in vitro and in humanized mice. J Hepatol 2012; 57: 1723.
  • 20
    Syder AJ, Lee H, Zeisel MB, Grove J, Soulier E, Macdonald J, et al. Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors. J Hepatol 2011; 54: 4855.
  • 21
    Dao Thi VL, Granier C, Zeisel MB, Guerin M, Mancip J, Granio O, et al. Characterization of hepatitis C virus particle subpopulations reveals multiple usage of the scavenger receptor BI for entry steps. J Biol Chem 2012; 287: 3124231257.
  • 22
    Zahid MN, Turek M, Xiao F, Thi VL, Guerin M, Fofana I, et al. The post-binding activity of scavenger receptor BI mediates initiation of hepatitis C virus infection and viral dissemination. Hepatology 2012 18 Oct. doi:10.1002/hep.26097.
  • 23
    Dreux M, Pietschmann T, Granier C, Voisset C, Ricard-Blum S, Mangeot PE, et al. High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI. J Biol Chem 2006; 281: 1828518295.
  • 24
    von Hahn T, Lindenbach BD, Boullier A, Quehenberger O, Paulson M, Rice CM, McKeating JA. Oxidized low-density lipoprotein inhibits hepatitis C virus cell entry in human hepatoma cells. HEPATOLOGY 2006; 43: 932942.
  • 25
    Jiang X, Yang Z, Chandrakala AN, Pressley D, Parthasarathy S. Oxidized low density lipoproteins—do we know enough about them? Cardiovasc Drugs Ther 2011; 25: 367377.
  • 26
    Parthasarathy S, Raghavamenon A, Garelnabi MO, Santanam N. Oxidized low-density lipoprotein. Methods Mol Biol 2010; 610: 403417.
  • 27
    Goldstein JL, Ho YK, Basu SK, Brown MS. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc Natl Acad Sci U S A 1979; 76: 333337.
  • 28
    Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955; 34: 13451353.
  • 29
    Esterbauer H, Striegl G, Puhl H, Rotheneder M. Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Radic Res Commun 1989; 6: 6775.
  • 30
    Ciesek S, von Hahn T, Colpitts CC, Schang LM, Friesland M, Steinmann J, et al. The green tea polyphenol, epigallocatechin-3-gallate, inhibits hepatitis C virus entry. HEPATOLOGY 2011; 54: 19471955.
  • 31
    Ciesek S, Steinmann E, Iken M, Ott M, Helfritz FA, Wappler I, et al. Glucocorticosteroids increase cell entry by hepatitis C virus. Gastroenterology 2010; 138: 18751884.
  • 32
    Ciesek S, Westhaus S, Wicht M, Wappler I, Henschen S, Sarrazin C, et al. Impact of occludin intra- and inter-species variation on its co-receptor function for authentic hepatitis C virus particles. J Virol 2011; 85: 76137621.
  • 33
    Gottwein JM, Scheel TK, Jensen TB, Lademann JB, Prentoe JC, Knudsen ML, et al. Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs. HEPATOLOGY 2009; 49: 364377.
  • 34
    Catanese MT, Ansuini H, Graziani R, Huby T, Moreau M, Ball JK, et al. Role of scavenger receptor class B type I in hepatitis C virus entry: kinetics and molecular determinants. J Virol 2010; 84: 3443.
  • 35
    Bankwitz D, Steinmann E, Bitzegeio J, Ciesek S, Friesland M, Herrmann E, et al. Hepatitis C virus hypervariable region 1 modulates receptor interactions, conceals the CD81 binding site, and protects conserved neutralizing epitopes. J Virol 2010; 84: 57515763.
  • 36
    Grove J, Nielsen S, Zhong J, Bassendine MF, Drummer HE, Balfe P, McKeating JA. Identification of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies. J Virol 2008; 82: 1202012029.
  • 37
    Puente Navazo MD, Daviet L, Ninio E, McGregor JL. Identification on human CD36 of a domain (155-183) implicated in binding oxidized low-density lipoproteins (Ox-LDL). Arterioscler Thromb Vasc Biol 1996; 16: 10331039.
  • 38
    Levitan I, Volkov S, Subbaiah PV. Oxidized LDL: diversity, patterns of recognition, and pathophysiology. Antioxid Redox Signal 2010; 13: 3975.
  • 39
    Nakhjavani M, Mashayekh A, Khalilzadeh O, Asgarani F, Morteza A, Omidi M, Froutan H. Oxidized low-density lipoprotein is associated with viral load and disease activity in patients with chronic hepatitis C. Clin Res Hepatol Gastroenterol 2011; 35: 111116.
  • 40
    Pfutzner A, Efstrathios K, Lobig M, Armbruster FP, Hanefeld M, Forst T. Differences in the results and interpretation of oxidized LDL cholesterol by two ELISA assays—an evaluation with samples from the PIOstat study. Clin Lab 2009; 55: 275281.